Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)
Sponsor: NS Pharma, Inc.
Terminated
The study was stopped due to a business decision.
Other Post-essential Thrombocythemia Myelofibrosis trials with similar outcome
Browse all Post-essential Thrombocythemia Myelofibrosis trials
This PHASE2 trial investigates Post-essential Thrombocythemia Myelofibrosis and Post-polycythemia Vera Myelofibrosis and is currently terminated or withdrawn. NS Pharma, Inc. leads this study, which shows 20 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 15 earlier versions
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2021 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NS Pharma, Inc.
- Nippon Shinyaku Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Ampang, Malaysia , Augsburg, Germany , Banpo-dong, South Korea , Bath, United Kingdom , Bağcılar, Turkey (Türkiye) , Brescia, Italy , Bydgoszcz, Poland , Catania, Italy , Edinburgh, United Kingdom and 34 more locations